Retrophin, Inc.
(NASDAQ : RTRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.10%178.021.3%$463.22m
CELGCelgene Corporation
0.88%97.361.3%$421.81m
GILDGilead Sciences, Inc.
1.27%67.200.9%$393.42m
BIIBBiogen Inc.
2.09%232.431.3%$354.80m
ILMNIllumina, Inc.
1.84%350.333.5%$272.87m
REGNRegeneron Pharmaceuticals, Inc.
1.98%311.292.6%$233.52m
AAgilent Technologies, Inc.
0.66%70.431.6%$213.47m
VRTXVertex Pharmaceuticals Incorporated
2.11%173.821.9%$198.29m
ARRYArray BioPharma Inc.
56.24%46.238.2%$185.21m
EXASExact Sciences Corporation
0.94%110.8125.3%$184.59m
ALXNAlexion Pharmaceuticals, Inc.
2.27%120.612.0%$176.07m
BMRNBioMarin Pharmaceutical Inc.
4.18%84.224.3%$136.28m
MRTXMirati Therapeutics Inc.
6.33%100.232.5%$113.79m
IONSIonis Pharmaceuticals, Inc.
4.38%64.818.2%$97.17m
INCYIncyte Corporation
5.39%81.902.5%$92.01m

Company Profile

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.